Regulatory Webinars

  1. The Power of AI To Advance Digital Health Innovation 6/18/2026

    Discover how leaders from Pfizer, Mayo Clinic, and the FDA use AI to advance digital endpoints in this 4-video recap of ADDS 2026. Learn to turn AI insights into scalable, regulatory-ready solutions.

  2. Best Practices For Medication Barcoding In Clinical Trials 6/10/2026

    Investigational products present a distinctly high-risk environment for labeling and barcoding. Explore best practices for barcoding solutions that allow for improved medication safety in clinical trials.

  3. Closing The Gaps: Strengthening Safety Data Flow In Outsourced Clinical Trials 6/3/2026

    Outsourced clinical trials risk safety missteps when communication falters. Clear, detailed data flow processes help prevent lost context, reduce misclassification, and support more accurate safety decisions across CROs and internal teams.

  4. AI Meets Informed Consent: Opportunity, Risk, and What IRBs Need to See 5/14/2026

    Expert perspectives on IRB oversight, health literacy, and research ethics offer practical guidance to strengthen consent, protect participants, and align compliance with real-world research.

  5. How To Best Navigate The Global Clinical Trial Registry Ecosystem 5/12/2026

    This presentation is your GPS, guiding you on a path that includes harmonization initiatives intended to improve transparency and data consistency across registries.

  6. Human Abuse Potential: Selecting A Positive Control 5/8/2026

    Choosing an effective positive control in HAP studies is critical but not always straightforward. Learn how to justify comparator and dose selection.

  7. Human Abuse Potential: CSS Interactions 5/8/2026

    Learn how, by embedding FDA engagement into the development process, sponsors can strengthen their abuse potential assessment and support smoother regulatory review.

  8. Pharmacy Considerations For Early Phase Trials 5/8/2026

    This presentation explores practical pharmacy considerations in early-phase clinical trials, offering real-world insights from experienced clinical research pharmacists.

  9. Definitive QT Evaluation - Clinical And Operational Considerations 5/8/2026

    QT strategy decisions affect timelines, cost, and regulatory outcomes. This presentation examines when early QT data can support a waiver, how guidance updates influence study design, and more.

  10. Human Abuse Potential: Subjective Ratings 5/5/2026

    Accurate subjective ratings are central to Human Abuse Potential studies. Learn how Visual Analog Scales are administered, what influences responses, and why data collection practices are essential.